INAB IN8BIO, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1740279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.1%
TTM EPS YoY80.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-141.8%
ROA-109.4%
ROIC (approx.)-1,362.1%
Asset turnover—
Leverage & solvency
Liabilities / assets24.2%
Debt / equity0.00x
Current ratio5.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-26.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.60M | $2.49M | $2.61M | $2.65M | $2.10M | $2.49M | $2.97M | $3.59M |
| SG&A expense | $2.12M | $2.44M | $2.65M | $2.38M | $1.86M | $2.71M | $2.69M | $2.63M |
| Operating income | -$4.59M | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | -$5.55M | -$6.16M |
| Net income | -$4.59M | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | -$5.55M | -$6.16M |
| EBITDA | -$4.09M | -$4.48M | -$4.84M | -$4.70M | -$3.65M | -$4.79M | -$5.29M | -$5.91M |
| EPS (basic) | -0.24 | -0.25 | -0.26 | — | -0.85 | -1.24 | -2.16 | — |
| EPS (diluted) | -0.24 | -0.25 | -0.26 | — | -0.85 | -1.24 | -2.16 | — |
| Weighted avg. shares (diluted) | 19.47M | 19.47M | 19.47M | — | 4.54M | 4.12M | 2.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.15M | $18.13M | $22.16M | $27.31M | $10.96M | $13.50M | $12.16M | $11.39M |
| Current assets | $15.19M | $18.50M | $22.66M | $27.88M | $11.77M | $13.74M | $12.72M | $12.58M |
| PP&E, net | $1.34M | $1.60M | $1.62M | $1.86M | $2.10M | $2.35M | $2.60M | $2.86M |
| Total assets | $18.70M | $21.75M | $26.27M | $32.28M | $16.77M | $19.37M | $19.87M | $20.94M |
| Current liabilities | $2.63M | $2.25M | $2.16M | $3.16M | $1.70M | $1.95M | $2.96M | $3.08M |
| Total liabilities | $4.52M | $3.38M | $3.48M | $4.72M | $3.58M | $4.13M | $5.99M | $6.47M |
| Shareholders' equity | $14.17M | $18.36M | $22.78M | $27.56M | $13.19M | $15.24M | $13.88M | $14.48M |
| Shares outstanding | 9.86M | 9.85M | 9.85M | 9.77M | 4.59M | 4.08M | 81.26M | 2.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.93M | -$3.75M | -$4.95M | -$2.14M | -$3.52M | -$3.93M | -$3.12M | -$4.03M |
| Capital expenditure | — | — | — | — | $0 | $0 | $0 | — |
| Free cash flow | — | — | — | — | -$3.52M | -$3.93M | -$3.12M | — |
| Investing cash flow | $1,000 | -$233,000 | -$9,000 | $0 | $0 | $0 | $0 | -$33,000 |
| Financing cash flow | -$56,000 | -$51,000 | -$195,000 | $18.49M | $989,000 | $5.27M | $3.89M | $11.19M |
| Depreciation & amortization | $500,000 | $300,000 | $245,000 | $245,000 | $200,000 | $300,000 | $256,000 | $251,000 |
| Stock-based compensation | $397,000 | $352,000 | $401,000 | $711,000 | $692,000 | $955,000 | $831,000 | $825,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.